RT Book, Section A1 Shalabi, Reem Abozena A1 Frame, James N. A2 Boyiadzis, Michael M. A2 Frame, James N. A2 Kohler, David R. A2 Fojo, Tito SR Print(0) ID 1128367588 T1 Indications for Bone-Modifying Agents in Hematology-Oncology T2 Hematology-Oncology Therapy, 2e YR 2016 FD 2016 PB McGraw-Hill Education PP New York, NY SN 9780071637893 LK hemonc.mhmedical.com/content.aspx?aid=1128367588 RD 2024/10/11 AB Primary Indications in Patients with CancerTo protect bone from new metastatic lesionsTo treat hypercalcemia of malignancyTo prevent treatment-related bone demineralization, osteolysis, and pathologic fracturesTo treat osteolytic lesions, decrease the incidence of pathologic fractures, prevent skeletal deformities, and prevent and decrease the severity of pain